000			03940cam a22003855c 4500
001			84765
003			ES-MaUEC
005			20230207040439.0
007			cr nn 008mamaa
008			151019s2016 gw | s |||| 0|eng d
020			_a9783319214856
040			_aES-MaUEC
050		4	_aRC280.P7 _b2016 EB
082	0	4	_a616.6
245	0	4	_aThe Prostate Cancer Dilemma : _bSelecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy _cedited by Nelson N Stone, E David Crawford
250			_a1st ed.
260			_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XIV, 206 p.) _b55 ilustraciones, 49 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPart One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions
520	3		_aThis text provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative and in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs is addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of this new technology in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a very useful resource for physicians and researchers dealing with, and interested in this challenging malignancy. Chapters are written by experts in their fields and include the most up to date scientific and clinical information as well as links to procedural video content
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aPróstata _xCáncer _0comprobar BNE19901355947 _2embne _9182337
700	1		_aStone, Nelson N. _eeditor literario _997201 _0Local
700	1		_aCrawford, E. David. _eeditor literario _935787 _0comprobar BNE20032424248
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-21485-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319214856
907			_a.b12940434 _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b04-04-17 _cm _dz _ek _feng _ggw _h4
945			_aRC280.P7 T447 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11584865 _z06-04-17
999			_c84765 _d84765 _x1